ADC Therapeutics(US:ADCT)2026-03-10 11:58Financial Performance - Fourth quarter 2025 net product revenue was approximately $22.3 million, and full year revenue was $73.6 million, compared to $16.4 million and $69.3 million for the same periods in 2024, reflecting a quarter-over-quarter increase driven by variability in customer ordering[8] - Product revenues for Q4 2025 reached $22,312,000, a 36% increase from $16,386,000 in Q4 2024[36] - Total revenue for the year 2025 was $81,357,000, compared to $70,837,000 in 2024, reflecting a 15% growth[36] - The net loss for the fourth quarter 2025 was $6.4 million, or $0.04 per share, compared to a net loss of $30.7 million, or $0.29 per share in the same period of 2024[14] - The net loss for Q4 2025 was $6,409,000, significantly improved from a net loss of $30,727,000 in Q4 2024[36] - The adjusted net loss for the twelve months ended December 31, 2025, was $91,675,000, a decrease from $111,379,000 in 2024, reflecting a reduction of approximately 17.7% year-over-year[41] - The net loss per share, basic and diluted, for the twelve months ended December 31, 2025, was $1.12, down from $1.62 in 2024, showing a 30.9% improvement[41] Research and Development - Research and Development (R&D) expenses decreased to $18.2 million for the fourth quarter and $104.0 million for the full year 2025, down from $27.1 million and $109.6 million in 2024, primarily due to reduced spending on discontinued programs[9] - Research and development expenses for the year 2025 were $104,005,000, a slight decrease from $109,633,000 in 2024[36] - The company plans to assess regulatory and compendia strategies for ongoing investigator-initiated trials evaluating ZYNLONTA in additional B-cell malignancies[7] Cash and Liquidity - Cash and cash equivalents as of December 31, 2025, were $261.3 million, up from $250.9 million at the end of 2024, providing a cash runway expected to last at least into 2028[16] - The company anticipates a cash runway extending at least to 2028, assuming minimum liquidity requirements are maintained[34] - Cash and cash equivalents increased to $261,338,000 as of December 31, 2025, up from $250,867,000 in 2024[38] Operating Expenses - Total operating expenses for the fourth quarter 2025 were $41.0 million, down from $49.3 million in the same period of 2024, with adjusted total operating expenses at $39.4 million compared to $46.6 million in 2024[13] - Operating expenses decreased by 17% in Q4 2025 to $40,977,000 from $49,346,000 in Q4 2024[40] Strategic Initiatives - The company amended its HealthCare Royalty financing agreement, reducing the change of control payment from $750 million to $150 million through the end of 2027[17] - The company is undergoing a strategic reprioritization and restructuring plan approved by the Board of Directors on June 11, 2025, aimed at improving operational efficiency[41] - Restructuring charges for the twelve months ended December 31, 2025, amounted to $7,365,000, with no charges reported in 2024, highlighting a new strategic initiative[41] - Impairment charges for the twelve months ended December 31, 2025, were $5,755,000, with no charges in 2024, indicating asset write-downs associated with restructuring efforts[41] Clinical Trials - LOTIS-5 Phase 3 topline results are anticipated in the second quarter of 2026, with full results expected by the end of 2026, and potential regulatory approval in mid-2027[4] - The LOTIS-7 trial reported an 89.8% best overall response rate and a 77.6% complete response rate among 49 efficacy evaluable patients[5] Shareholder Information - Share-based compensation expense for the three months ended December 31, 2025, was $1,937,000, compared to $2,779,000 in 2024, representing a decrease of 30.3%[41] - The weighted average shares outstanding, basic and diluted, increased to 127,067,540 for the twelve months ended December 31, 2025, from 97,159,966 in 2024, reflecting a 30.7% increase[41]